Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025CancersOpen Access

Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

HJH. P. JoshiMSM. Saeed Sheikh

Discussion

Loading...

Member takes

Overview

Review examines the impact of EGFR mutations on cell death and metabolic changes in NSCLC, highlighting treatment challenges.

Key Points

  • EGFR mutations in lung cancer lead to altered cell death pathways and metabolic changes, affecting prognosis.
  • Tyrosine kinase inhibitors effectively induce cell death in EGFR-mutant NSCLC but encounter resistance issues in treatment.
  • Understanding metabolic reprogramming in tumor cells can guide personalized therapies for advanced lung cancer.
  • Emerging strategies aim to overcome resistance to EGFR-TKIs and address limitations of immunotherapy in this cancer type.

Cite This Study

Joshi et al. (2025) studied this question.

synapsesocial.com/papers/68c1d5ef54b1d3bfb60f8acfhttps://doi.org/10.3390/cancers17172791
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systemic treatment of EGFR-mutated non-small cell lung cancer2024
  2. 2Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.2026
  3. 3EGFR-Directed Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer2025
  4. 4Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management2025 · 22 citations
  5. 5Research progress on the mechanism and intervention strategies of MET protein in regulating the resistance to targeted therapy for EGFR-mutated non-small cell lung cancer2026